Hence, increased intrinsic basal ROS levels in EGFR-positive GBM and the crosstalk between EGFR and the GSH system underlie the rationale to investigate a pro-oxidant Trx/GSH co-targeting strategy in EGFR-positive GBM. This evidence concerns the gene TXN and glioblastoma.